Efficacy of Different Oncolytic Vaccinia Virus Strains for the Treatment of Murine Peritoneal Mesothelioma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jan 23

PMID 38254857

Authors

Can Yurttas

Julia Beil

Susanne Berchtold

Irina Smirnow

Linus D Kloker

Bence Sipos

Markus W Loffler

Alfred Konigsrainer

Andre L Mihaljevic

Ulrich M Lauer

Karolin Thiel

Affiliations

Soon will be listed here.

Abstract

Effective treatment options for peritoneal surface malignancies (PSMs) are scarce. Oncolytic virotherapy with recombinant vaccinia viruses might constitute a novel treatment option for PSM. We aimed to identify the most effective oncolytic vaccinia virus strain in two murine mesothelioma cell lines and the oncolytic potential in a murine model of peritoneal mesothelioma. Cell lines AB12 and AC29 were infected in vitro with vaccinia virus strains Lister (GLV-1h254), Western Reserve (GLV-0b347), and Copenhagen (GLV-4h463). The virus strain GLV-0b347 was shown most effective in vitro and was further investigated by intraperitoneal (i.p.) application to AB12 and AC29 mesothelioma-bearing mice. Feasibility, safety, and effectiveness of virotherapy were assessed by evaluating the peritoneal cancer index (PCI), virus detection in tumor tissues and ascites, virus growth curves, and comparison of overall survival. After i.p. injection of GLV-0b347, virus was detected in both tumor cells and ascites. In comparison to mock-treated mice, overall survival was significantly prolonged, ascites was less frequent and PCI values declined. However, effective treatment was only observed in animals with limited tumor burden at the time point of virus application. Nonetheless, intraperitoneal virotherapy with GLV-0b347 might constitute a novel therapeutic option for the treatment of peritoneal mesothelioma. Additional treatment modifications and combinational regimes will be investigated to further enhance treatment efficacy.

References

Elias D, Gilly F, Boutitie F, Quenet F, Bereder J, Mansvelt B . Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2009; 28(1):63-8. DOI: 10.1200/JCO.2009.23.9285. View

Ottow R, Steller E, Sugarbaker P, Wesley R, Rosenberg S . Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models. Cell Immunol. 1987; 104(2):366-76. DOI: 10.1016/0008-8749(87)90038-4. View

Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M . Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):256-266. DOI: 10.1016/S1470-2045(20)30599-4. View

Yan T, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009; 27(36):6237-42. DOI: 10.1200/JCO.2009.23.9640. View

Kelly E, Russell S . History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007; 15(4):651-9. DOI: 10.1038/sj.mt.6300108. View

Yonemura Y, Canbay E, Ishibashi H . Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. ScientificWorldJournal. 2013; 2013:978394. PMC: 3654240. DOI: 10.1155/2013/978394. View

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka R, Michielin O . Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017; 170(6):1109-1119.e10. PMC: 8034392. DOI: 10.1016/j.cell.2017.08.027. View

Van Cutsem E, Cervantes A, Adam R, Sobrero A, van Krieken J, Aderka D . ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8):1386-422. DOI: 10.1093/annonc/mdw235. View

Ranganathan P, Pramesh C, Aggarwal R . Common pitfalls in statistical analysis: Measures of agreement. Perspect Clin Res. 2017; 8(4):187-191. PMC: 5654219. DOI: 10.4103/picr.PICR_123_17. View

10.

Goere D, Souadka A, Faron M, Cloutier A, Viana B, Honore C . Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015; 22(9):2958-64. DOI: 10.1245/s10434-015-4387-5. View

11.

Carter M, Hartkopf A, Wagner A, Volmer L, Brucker S, Berchtold S . A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy. Front Mol Biosci. 2022; 9:826302. PMC: 8874275. DOI: 10.3389/fmolb.2022.826302. View

12.

Goradel N, Alizadeh A, Hosseinzadeh S, Taghipour M, Ghesmati Z, Arashkia A . Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses. Future Oncol. 2021; 18(2):245-259. DOI: 10.2217/fon-2021-0802. View

13.

Chesney J, Puzanov I, Collichio F, Singh P, Milhem M, Glaspy J . Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. J Immunother Cancer. 2023; 11(5). PMC: 10163510. DOI: 10.1136/jitc-2022-006270. View

14.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

15.

Miura J, Johnston F, Clark Gamblin T, Turaga K . Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol. 2014; 21(12):3947-53. DOI: 10.1245/s10434-014-3803-6. View

16.

Eveno C, Mojica K, Ady J, Thorek D, Longo V, Belin L . Gene therapy using therapeutic and diagnostic recombinant oncolytic vaccinia virus GLV-1h153 for management of colorectal peritoneal carcinomatosis. Surgery. 2015; 157(2):331-7. PMC: 4373422. DOI: 10.1016/j.surg.2014.09.008. View

17.

van Der Speeten K, Stuart O, Sugarbaker P . Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr Drug Discov Technol. 2009; 6(1):72-81. PMC: 2764866. DOI: 10.2174/157016309787581084. View

18.

Liu T, Galanis E, Kirn D . Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol. 2007; 4(2):101-17. DOI: 10.1038/ncponc0736. View

19.

Chua T, Yan T, Morris D . Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2008; 99(2):109-13. DOI: 10.1002/jso.21177. View

20.

van Driel W, Koole S, Sikorska K, Schagen van Leeuwen J, Schreuder H, Hermans R . Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018; 378(3):230-240. DOI: 10.1056/NEJMoa1708618. View